On March 25, Gelonghui | Xianruida Medical-B (06669.HK) issued an announcement. The stable and favorable state of production and research directly led to a rapid increase in annual revenue. For the year ended 31 December 2023, the company's revenue was approximately RMB 473.8 million, an increase of approximately 19.8% over the previous year. The company's core products, AcoArt Orchid & Dhalia and AcoArt Tulip & Litos, became the core source of the company's revenue. The adjusted net profit during the year was $42.435 million, an increase of 22.1% over the previous year.
The Group's R&D costs for the year ended 31 December 2023 were approximately RMB 190.1 million, an increase of approximately 3.4% over approximately RMB 183.8 million for the year ended 31 December 2022. The increase is mainly due to an increase in staff costs due to an increase in the number of R&D personnel.